12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Galvus vildagliptin regulatory update

The European Commission approved an application to extend the indication for Galvus vildagliptin from Novartis to treat Type II diabetes...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >